Learn More
PURPOSE To evaluate the efficacy of rituximab maintenance in 60- to 75-year-old patients with advanced follicular lymphoma responding to brief first-line chemoimmunotherapy followed by rituximab(More)
6629 Background: The FCR regimen (fludarabine, cyclophosphamide, rituximab) significantly improves the outcome of patients (pts) with chronic lymphocytic leukemia (CLL). However, myelotoxicity and(More)